Personalis Receives Buy Rating from Lake Street with $9.00 Price Target

Personalis (PSNL) receives a Buy rating from Lake Street with a $9.00 price target, up 59% from its current price of $5.64. The company's recent earnings report showed a quarterly revenue of $20.61 million and a GAAP net loss of $15.75 million. Corporate insider sentiment is negative, with an increase in insiders selling their shares over the past quarter.

Personalis Inc. (PSNL) received a "Buy" rating from Lake Street with a $9.00 price target, representing a 59% increase from its current price of $5.64. The analyst's bullish outlook was accompanied by a significant upward revision in the stock's valuation, reflecting the company's recent market performance and strategic focus.

In its latest earnings report, Personalis posted a quarterly revenue of $20.61 million, a notable improvement over the previous quarter. However, the company also reported a GAAP net loss of $15.75 million, highlighting the ongoing challenges in aligning with market expectations.

The company's mixed financial performance in Q2 2025 underscores its struggle to balance growth and profitability. Despite the revenue shortfall, Personalis' stock saw a modest increase of 0.72% in aftermarket trading following the earnings release, reaching $5.61.

Personalis' CEO Chris Hall emphasized the company's innovative approach and the potential of its NextPersonal test in transforming cancer care. The test's ultra-sensitivity allows it to detect residual cancer with unprecedented accuracy, positioning Personalis to capture a significant share of the minimal residual disease (MRD) market.

Analysts maintain a bullish consensus on PSNL, with price targets ranging from $5 to $9. The company's strategic focus on expanding its clinical testing capabilities and securing Medicare coverage for cancer indications further supports its long-term growth prospects.

However, the company faces continued revenue shortfalls and biopharma market challenges. Additionally, corporate insider sentiment is negative, with an increase in insiders selling their shares over the past quarter, potentially indicating a lack of confidence in the company's near-term performance.

In summary, Personalis' recent analyst rating and earnings report highlight the company's mixed financial performance and strategic focus on expanding its clinical testing capabilities. While the company faces ongoing challenges, its innovative approach and market potential suggest long-term growth prospects.

References:
[1] https://www.gurufocus.com/news/3040480/psnl-hc-wainwright-co-lowers-target-price-maintains-buy-rating-psnl-stock-news
[2] https://ca.investing.com/news/transcripts/earnings-call-transcript-personalis-q2-2025-reveals-revenue-miss-stock-steady-93CH-4138179